Significant association between tumor mutational burden and immune-related adverse events during immune checkpoint inhibition therapies
Open Access
- 9 March 2020
- journal article
- editorial
- Published by Springer Science and Business Media LLC in Cancer Immunology, Immunotherapy
- Vol. 69 (5), 683-687
- https://doi.org/10.1007/s00262-020-02543-6
Abstract
More than 2000 immuno-oncology agents are being tested or are in use as a result of the cancer immunotherapy revolution. Manipulation of co-inhibitory receptors has achieved tumor eradication in a minority of patients, but widespread immune-related adverse events (irAEs) compromised tolerance to healthy self-tissues in the majority. We have proposed that a major mechanism of irAEs is similar to a graft-versus-malignancy effect of graft-versus-host disease. To verify our hypothesis, we retrieved post-marketing data of adverse events from the U.S. Food and Drug Administration Adverse Event Reporting System. A significant positive correlation was revealed in 7677 patients between the reporting odds ratio of irAEs during immune checkpoint inhibitor therapy and the corresponding tumor mutational burden across 19 cancer types. These results can be interpreted to mean that the ICI drugs unleashed T cells against “altered-self,” self, and tumors resulting in better overall survival.Keywords
Funding Information
- Ministry of Human Capacities in Hungary (2018-1.2.1-NKP-00008)
- Canadian Institutes of Health Research (PS148588)
This publication has 21 references indexed in Scilit:
- Nivolumab Plus Ipilimumab in Patients With Advanced Melanoma: Updated Survival, Response, and Safety Data in a Phase I Dose-Escalation StudyJournal of Clinical Oncology, 2018
- Analysis of 100,000 human cancer genomes reveals the landscape of tumor mutational burdenGenome Medicine, 2017
- Anti-CTLA-4 therapy may have mechanisms similar to those occurring in inherited human CTLA4 haploinsufficiencyImmunobiology, 2015
- National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: I. The 2014 Diagnosis and Staging Working Group ReportTransplantation and Cellular Therapy, 2014
- Genetic Basis for Clinical Response to CTLA-4 Blockade in MelanomaNew England Journal of Medicine, 2014
- Control of minimal residual cancer by low dose ipilimumab activating autologous anti-tumor immunityPharmacological Research, 2014
- Signatures of mutational processes in human cancerNature, 2013
- Ipilimumab (Yervoy) and the TGN1412 catastropheImmunobiology, 2012
- The role of co-inhibitory signals in spontaneous tolerance of weakly mismatched transplantsImmunobiology, 2011
- Quantitative signal detection using spontaneous ADR reportingPharmacoepidemiology and Drug Safety, 2009